SOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS Patients

SOL-257Positive

AI Analysis

Summary

SOLA Biosciences Japan received a 6 billion yen grant from AMED to advance SOL-257, a gene therapy targeting TDP-43 function restoration in ALS patients. The funding will support development over five years.

Outcome Details

Grant awarded by AMED (Japan Agency for Medical Research and Development)

Importance:5/10

Sentiment:

0.60

gene therapyALSTDP-43Japangrant fundingAMED

Read the original article

Published by PR Newswire Biotech on September 28, 2026 6:00 AM

Read Original